ETFdb Logo
  • ETF Database
  • Channels
    • Themes
      • Active ETF
      • Alternatives Channel
      • Artificial Intelligence
      • China Insights
      • Climate Insights
      • Core Strategies
      • Crypto
      • Disruptive Technology
      • Energy Infrastructure
      • ETF Building Blocks
      • ETF Education
      • ETF Investing
      • ETF Strategist
      • Faith-Based Investing
      • Financial Literacy
      • Fixed Income
      • Free Cash Flow
      • Innovative ETFs
      • Invest Beyond Cash
      • Leveraged & Inverse
      • Modern Alpha
      • Portfolio Strategies
      • Tax Efficient Income
    • Asset Class
      • Equity
        • U.S. Equity
        • Int'l Developed
        • Emerging Market Equities
      • Alternatives
        • Gold/Silver/Critical Materials
        • Crypytocurrency
        • Currency
        • Volatility
      • Fixed Income
        • Investment Grade Corporates
        • US Treasuries & TIPS
        • High Yield Corporates
        • Int'l Fixed Income
    • ETF Ecosystem
    • ETFs in Canada
    • Market Outlook
    • Crypto ETF Hub
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Database Categories
    • Indexes
    • Scenario Analysis
    • Watchlists
    • Head-To-Head ETF Comparison Tool
    • Mutual Fund To ETF Converter
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
  • Research
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF of the Week Podcast
    • Gaining Perspective Podcast
    • ETF Prime Podcast
    • Video
  • Company
    • About VettaFi
    • Get VettaFi’ed
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Dual Impact Channel
  2. In 2023, Healthcare Could Be a Healthy Sector Bet
Dual Impact Channel
Share

In 2023, Healthcare Could Be a Healthy Sector Bet

Tom LydonJan 09, 2023
2023-01-09

The healthcare sector, the second-largest sector allocation in the S&P 500, performed significantly less poorly than the broader market in 2022 and that relative sturdiness has some market observers optimistic about the group’s 2023 prospects.

With that in mind, investors may want to evaluate exchange traded funds such as the IQ Healthy Hearts ETF (HART ) as tactical ideas in the new year. After all, history, and recent history at that, indicate healthcare stocks can be resilient in the face of macroeconomic headwinds.

“The reason it did so well is that people still need to pay for health insurance, drugs, and vaccines even when they are watching how much they spend. Profits in the sector tend to be stable even when hard times crimp earnings elsewhere, so the current environment, with its high inflation and rising interest rates, is a chance for the shares to shine,” reported Jacob Sonenshine for Barron’s.

As 2023 unfolds, HART investors could discover multiple factors working in their favor. For example, the ETF’s healthcare holdings, broadly speaking, are quality stocks with strong balance sheets and, in many cases, storied histories of dividend growth. Plus, investors don’t have to incur a valuation tax to embrace this ETF’s benefits.

“The good news is that some healthcare stocks, especially those of biopharma companies, still appear relatively cheap. In aggregate, prices of pharma stocks in the S&P 500 are at multiples of earnings about 10% below the S&P 500’s roughly 16 times, according to UBS data,” noted Barron’s.

Another issue that could work in favor of HART this year is coronavirus vaccine fatigue. That doesn’t imply diminished importance or relevance of the vaccine. Rather, investors are likely to demand more from pharmaceutical and biotech companies than COVID-19 treatments. Fortunately, many of HART’s pharma components have deep product pipelines or have the cash to make acquisitions to bolster those pipelines. Others have the benefit of long-running patent protection before generic producers can bring competing products to market.

Then there’s the earnings story. Analysts are expecting a majority of the 11 global industry classification standard (GICS) sectors will post lower earnings growth this year. It remains to be seen if the broader healthcare sector can avoid that dubious distinction, but what’s not up for debate is the fact that analysts expect several of HART’s marquee pharma holdings will post growing earnings per share (EPS) this year.

For more news, information, and analysis, visit the Dual Impact Channel.

Loading Articles...
Our Sites
  • VettaFi
  • Advisor Perspectives
  • ETF Trends
Tools
  • ETF Screener
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Database Pro
More Tools
  • Financial Advisor & RIA Center
Explore ETFs
  • ETF News
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Information
  • Contact Us
  • Terms of Use and Privacy Policy
  • © 2025 VettaFi LLC. All rights reserved.

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X